WP
SLN

Woodline Partners’s Silence Therapeutics SLN Stock Holding History

Woodline Partners’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-62,459
Closed -$324K – 1107
2025
Q3 		$324K Hold
62,459
– – ﹤0.01% 855
2025
Q2 		$362K Sell
62,459
-72,033
-54% -$309K ﹤0.01% 878
2025
Q1 		$379K Sell
134,492
-364,240
-73% -$1.78M ﹤0.01% 842
2024
Q4 		$3.43M Buy
498,732
+91,829
+23% +$1.18M 0.02% 561
2024
Q3 		$7.4M Buy
406,903
+316,041
+348% +$5.88M 0.06% 339
2024
Q2 		$1.73M Sell
90,862
-147,518
-62% -$3.14M 0.02% 433
2024
Q1 		$5.15M Buy
238,380
+189,108
+384% +$4.11M 0.05% 356
2023
Q4 		$856K Sell
49,272
-117,380
-70% -$1.32M 0.01% 412
2023
Q3 		$1.64M Sell
166,652
-72,708
-30% -$537K 0.02% 415
2023
Q2 		$1.32M Buy
239,360
+95,676
+67% +$577K 0.02% 466
2023
Q1 		$891K Buy
143,684
+20,643
+17% +$243K 0.01% 482
2022
Q4 		$1.88M Buy
123,041
+7,921
+7% +$104K 0.03% 489
2022
Q3 		$1.16M Buy
+115,120
New +$1.21M 0.02% 525

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Woodline Partners's SLN Position: Q4 2025 in Review

Woodline Partners sold out of Silence Therapeutics (SLN) in Q4 2025, closing a stake of 62,459 shares — an estimated $324K sold.

Woodline Partners first reported a position in SLN in Q3 2022 and held it in 13 quarters. The position peaked at $7.4M in Q3 2024. 58 funds tracked by Wall St. Rank hold SLN as of Q4 2025.

  • Woodline Partners reported no remaining Silence Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Woodline Partners sold 62,459 Silence Therapeutics shares in Q4 2025, an estimated $324K.
  • Woodline Partners first reported a position in Silence Therapeutics in Q3 2022 and held it in 13 quarters.
  • Woodline Partners's Silence Therapeutics position peaked at $7.4M in Q3 2024.
  • 58 funds tracked by Wall St. Rank held Silence Therapeutics as of Q4 2025.

Based on Woodline Partners's 13F filing for Q4 2025, filed 17 Feb 2026.